Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
- 5 October 2011
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 131 (2), 483-490
- https://doi.org/10.1007/s10549-011-1799-1
Abstract
Neutropenia is one of the most important dose-limiting toxicities and often the reason for dose reduction. In this study we aimed to assess whether chemotherapy-induced neutropenia could be a marker of efficacy and associate with increased survival. Data from a retrospective survey for early breast cancer patients in our hospital were reviewed. Three hundred and thirty-five patients who had been treated with six cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF) were studied. The association between chemotherapy-induced neutropenia and overall survival (OS) was assessed. According to a multivariate Cox model with time-varying covariates, hazard ratios of death were 0.434 (95% confidence interval (CI), 0.298–0.634; P < 0.001) for patients with mild neutropenia, and 0.640 (95% CI, 0.42–0.975; P = 0.038) for those with severe neutropenia. Neutropenia occurring in early breast cancer patients is an independent predictor of increased survival. These findings suggest that neutropenia in patients who receive chemotherapy is strongly associated with a better prognosis.Keywords
This publication has 40 references indexed in Scilit:
- Triple-negative breast cancer—current status and future directionsAnnals Of Oncology, 2009
- Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOXEuropean Journal Of Cancer, 2009
- Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinomaBritish Journal of Cancer, 2007
- Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trialsThe Lancet Oncology, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancerBritish Journal of Cancer, 2003
- Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM groupAnnals Of Oncology, 2003
- Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMFBritish Journal of Cancer, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancerBritish Journal of Cancer, 1997